SCENTinel: A Rapid Smell Test for COVID-19 Surveillance

项目摘要 脱发是COVID-19的主要症状，基于自我报告的初步证据表明， 化学感觉丧失是普通人群中COVID-19的敏感预测因子，比发烧更敏感。 然而，考虑到对化学感觉变化的自然缺乏意识，自我报告低估了真实的 与客观测试相比，COVID-19患者嗅觉丧失的患病率降低了20%。所以我们 建议测试和部署一种快速客观的嗅觉能力测量方法，SCENTinel测试，其灵感来自于 我们团队之前开发的NIH气味识别测试。SCENTinel是一种廉价的， 和方便的气味测试，用于对人群进行COVID-19监测， 三个气味损失因素：气味检测、气味强度和气味识别。它是为实际应用而设计的， 几种情况下，包括高密度地区，如社区医疗点，大学，亚急性护理 设施，以及工业和非工业工作场所。我们的多学科团队拥有以下专业知识： 了解味觉和嗅觉，开发和验证化学感觉测试，以及研究广泛的 COVID-19的病理学。该小组由Monell化学感官中心的MPI道尔顿领导， 人类嗅觉和设计嗅觉测试的专家;来自天普大学的MPI Parma是 COVID-19嗅觉丧失，是全球化学感觉研究联盟的主席，并拥有以下方面的专业知识： 在快速变化的情况下进行研究;西北大学的Schalet博士和他的团队， 博士Chun和他在耶鲁大学的团队，以及其他建立和感兴趣的合作伙伴（福克斯亚急性 养老院，荷美尔食品）。我们的团队还包括Monell的技术转让总监 中心，奥莱利博士，以探索潜在的合作伙伴和扩大SCENTinel部署全国。Reed医生 Monell化学传感中心的研究人员将直接与数据协调中心合作， 管理大型共享NIH数据集的经验。所有人都将与NIH项目科学家密切合作。这 该提案旨在a）微调SCENTinel预测阳性COVID-19诊断测试的能力; B）检查 在阳性诊断测试之前，作为COVID-19早期阶段的标志的边缘嗅觉丧失;以及c） 用重测信度测量和NIH的验证来评估测试的心理测量学效度 气味识别测试。总之，这些目标将建立一个标准化的协议， SCENTinel是一种快速、客观的气味测试，可轻松纳入COVID-19现场测试 全国的中心、学校和工作场所。此外，它还将为早发性 与确诊的COVID-19诊断相关的化学感受症状，提供了一种至关重要的手段， 来控制COVID-19的传播

PROJECT SUMMARY Smell loss is a predominant symptom of COVID-19, and initial evidence based on self-reports suggests that chemosensory loss is a sensitive predictor of COVID-19 in the general population, more so than fever. However, given the natural lack of awareness of chemosensory changes, self-reports underestimate the true prevalence of smell loss in patients with COVID-19 by 20% compared to an objective test. Therefore, we propose testing and deploying a rapid and objective measure of smell ability, the SCENTinel test, inspired by the NIH Toolbox® Odor Identification Test that our team previously developed. SCENTinel is an inexpensive, and convenient smell test for COVID-19 surveillance of the population that quickly and easily assesses three smell loss factors: odor detection, odor intensity, and odor identification. It is designed for practical use in several contexts, including high-density areas such as community medical sites, universities, subacute care facilities, and both industrial and nonindustrial workplaces. Our multi-disciplinary team has expertise in understanding taste and smell, developing and validating chemosensory tests, as well as studying the broad symptomatology of COVID-19. The group is led by MPI Dalton from the Monell Chemical Senses Center, an expert in human olfaction and designing olfactory tests; MPI Parma from Temple University is an expert in COVID-19 smell loss, is the Chair of the Global Consortium for Chemosensory Research, and has expertise in conducting research in rapidly changing situations; Dr. Schalet and his team at Northwestern University and Dr. Chun and his team at Yale University, among the other established and interested partners (Fox subacute nursing homes, Hormel Food). Our team also includes the Director of Technology Transfer at the Monell Center, Dr. O’Leary, to explore potential partners and expand SCENTinel deployment nationwide. Dr. Reed from the Monell Chemical Senses Center will work directly with the Data Coordination Center, drawing on her experience in managing large shared NIH datasets. All will work closely with the NIH Project Scientist. This proposal aims to a) fine-tune SCENTinel’s ability to predict a positive COVID-19 diagnostic test; b) examine marginal smell loss as a sign of the earliest phases of COVID-19, before a positive diagnostic test; and c) assess the test’s psychometric validity with test-retest reliability measures and validation against the NIH Toolbox® Odor Identification Test. Together, these aims will establish a standardized protocol for use of SCENTinel as a rapid and objective smell test that can easily be incorporated into onsite COVID-19 testing centers, schools, and workplaces nationwide. Furthermore, it will provide key insights into early-onset chemosensory symptoms in relation to a confirmed COVID-19 diagnosis, providing a crucially needed means to contain the spread of COVID-19.